AzTrials
AzTrials

Cervical Spinal Cord InjuryEarly Phase 1NCT07299734

Feasibility and Safety of a Combined Augmented Reality and Functional Electrical Stimulation System

A Early Phase 1 study testing AR + FES in people with Cervical Spinal Cord Injury, run by University Health Network, Toronto at 1 site in Canada.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Cervical spinal cord injury (cSCI) can result in substantial loss of upper-limb function, with associated socio-economic impact on affected individuals and the healthcare system. Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Cervical Spinal Cord Injury
What is being tested?
AR + FES
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
7 participants
Where
1 siteCanada
Study dates
Jan 2026to Oct 2026
Phase
Early Phase 1
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Chronic cervical SCI
  • Any level or severity of cervical SCI, traumatic or non-traumatic
  • Can carry out object manipulations but with visible impairment (i.e., 5-25 on the GRASSP Prehension Performance sub-score).

Who cannot join

  • Any disease or injury other than the SCI that may be affecting grasping performance.
  • Individuals with any self-reported FES contraindications (pacemakers, implantable defibrillator, implanted neurostimulation device, metallic implants in the stimulated areas, cardiac conditions, epilepsy, uncontrolled seizures, wounds or fractures on the target limb)
  • Inability to understand the study procedures
  • Muscles do not respond to FES to produce grasping movements
  • Currently participating in another upper limb rehabilitation intervention study (regular physical and occupational therapy is permitted).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Sharmini Atputharaj, MSc contact

416-597-3422 ext. 6119

Sharmini.Atputharaj@uhn.ca

Canada1 site, 1 recruiting
  • Lyndhurst Centre, Toronto Rehabilitation Institute - University Health Network

    Toronto, Ontario

    Sharmini Atputharaj, MSc, 416-597-3422 ext. 6119, Sharmini.Atputharaj@uhn.ca

    Recruiting

Other trials in Canada

About this study

Official title: Assessing the Feasibility and Safety of a Combined Closed Loop Functional Electrical Stimulation and Augmented Reality System for Individuals With Cervical Spinal Cord Injury

Cervical spinal cord injury (cSCI) can result in substantial loss of upper-limb function, with associated socio-economic impact on affected individuals and the healthcare system. Evidence suggests that non-invasive neuromodulation such as functional electrical stimulation (FES) therapy can contribute to regaining upper-limb function, which is a top priority for this population. This pilot study will involve individuals with cSCI using a device that combines augmented reality (AR) and functional electrical stimulation (FES) for 20, one-hour sessions over a 10-week period. The sessions will include upper-limb rehabilitation where individuals will interact with different objects with the aid of the AR +FES system. The primary objective is to assess safety and feasibility, measured by the absence of serious adverse events and participants' ability to independently set up and use the system. Secondary objectives include adherence to the intervention and user feedback through structured interviews. Exploratory outcomes will examine preliminary efficacy using clinical measures such as the Spinal Cord Independence Measure (SCIM) and the Graded Redefined Assessment of Strength, Sensation and Prehension (GRASSP).

Being tested
AR + FES
Keywords
Cervical spinal cord injury, Augmented reality, Functional electrical stimulation, Neuromodulation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AR + FESDevice

    Within each one-hour experimental session, participants will interact with different objects (e.g. block, credit card, marble). They will be wearing an augmented reality (AR) headset and electrodes will be placed over finger flexors, thumb flexors and finger extensors muscles. The AR headset will track hand posture and use the difference between the actual posture and a target posture to regulate functional electrical stimulation (FES) delivered via the electrodes.

Study groups in NCT07299734
Study groupRoleWhat they receive
Single groupExperimentalParticipants will go through 1 screening session, 20 experimental sessions (2 sessions per week for 10 weeks), 1 discharge assessment, and 1 follow up assessment (one month after the last experimental session).
Receives: Device: AR + FES

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Adverse events

    Presence of adverse and serious adverse events. These will be recorded during each session. The criterion for success is no study-related serious adverse events and no study-related adverse events that cannot be alleviated by stopping electrical stimulation.

    Measured: Week 1 to week 14.

  2. Feasibility - Set-up time

    The study will track independence with the system by assessing set-up time.

    Measured: During experimental sessions from week 1 to week 10.

  3. Feasibility - Assistance required.

    The study will track independence with the system by assessing the number of times assistance is requested.

    Measured: During experimental sessions from week 1 to week 10.

Secondary outcomes (2)
  1. Adherence

    Number of missed sessions.

    Measured: During experimental sessions from week 1 to week 10.

  2. User feedback

    Structured and semi-structured interviews.

    Measured: Discharge assessment at week 10.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Dec 2025
  2. Study startJan 2026 (estimated)
  3. Primary completionOct 2026 (estimated)
  4. Study completionOct 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Early Phase 1
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
7 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07299734
Sponsor's protocol ID
25-5898
Status last verified
Nov 2025
First submitted
25 Nov 2025
Last updated
23 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: De-identified coded study data may be used or shared with other researchers for future studies. Directly identifying information will be replaced by a number, which will be applied to the study data. The participant key matching the code to the participant will be kept by the UHN study team. This may include storing the coded study data in controlled-access databases or open access, publicly accessible databases.

Questions about this trial

What is this clinical trial studying?

A Early Phase 1 study testing AR + FES in people with Cervical Spinal Cord Injury, run by University Health Network, Toronto at 1 site in Canada.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 23 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sharmini Atputharaj, MSc (416-597-3422 ext. 6119, Sharmini.Atputharaj@uhn.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Adverse events (time frame: Week 1 to week 14.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 23 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in